With the small sample size for the NASH 700mg it could have skewed for any number of reasons. For instance the inclusion/exclusion criteria makes no mention of the CCR5 Delta 32 gene variations. Since leronlimab does less for the single allele variation and nothing for the double allele variation those patients should have been excluded. If a few were present on the 700mg side but not placebo that could have thrown off results drastically. Amarex may not have cared enough to do it right.